Divi's Laboratories Ltd. is a high-risk Pharmaceuticals company based in India. Specializing in specialty and generic drug manufacturing, their sales are primarily in Europe, North America, India, and Asia. Divi's Laboratories operates in three segments: Generic APIs, Custom Synthesis, and Nutraceuticals. With a risk rating score of 32.8, the company is focused on growth through mergers and acquisitions to enhance their research, development, manufacturing, and marketing capabilities. Their ESG score highlights their commitment to sustainability and governance practices.